Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | LDHA | P00338 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | FABP7 | O15540 | 1/20 | 0.54 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | AGXT | P21549 | 2/20 | 0.53 |
| ▸ | MMP9 | P14780 | 2/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP12 | P39900 | 1/20 | 0.51 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11851173 | 0.98 | NPC1 (0.57) | NPC1POLBRAB9ASMN1; SMN2ALDH1A1 | |
| Hydrazine SCHEMBL8834679 | 0.96 | NPC1 (0.56) | NPC1POLBRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL22028110 | 0.94 | LTA4H (0.58) | NPC1POLBRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3758807 | 0.86 | ALDH1A1 (0.60) | NPC1POLBRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL292834 | 0.86 | ALDH1A1 (0.60) | NPC1POLBRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL8641118 | 0.85 | NPC1 (0.56) | NPC1POLBRAB9ASMN1; SMN2ALDH1A1 | |
| Acetic Acid SCHEMBL1868801 | 0.85 | ALDH1A1 (0.63) | NPC1POLBRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7699400 | 0.84 | LDHA (0.46) | NPC1POLBRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1871228 | 0.84 | ALDH1A1 (0.62) | NPC1POLBRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL112518 | 0.84 | ALDH1A1 (0.62) | NPC1POLBRAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1508 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035402-A1 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | ZIKANI THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | claimed |
| US-12060334-B2 | 3-substituted phenazine derivatives as antimicrobial agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-08-13 | — | — | US | claimed |
| US-11634449-B2 | Macrolides and methods of their preparation and use | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-04-25 | — | — | US | claimed |
| EP-3649135-B1 | SYNTHESIS OF HALICHONDRINS | HARVARD COLLEGE (US) | 2022-12-28 | — | — | EP | claimed |
| US-20220332747-A1 | MACROLIDES AND METHODS OF THEIR PREPARATION AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-10-20 | — | — | US | claimed |
| EP-3291676-B1 | MITRAGYNINE ANALOGS AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-08-17 | — | — | EP | claimed |
| US-11241435-B2 | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis | THE GENERAL HOSPITAL CORPORATION (US) | 2022-02-08 | — | — | US | claimed |
| EP-3172213-B1 | MACROCYCLIC KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2021-09-22 | — | — | EP | claimed |
| EP-3171874-B1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2020-11-18 | — | — | EP | claimed |
| EP-3063164-B1 | SYNTHETIC ROUTE TO 2'-DEOXY-2',2'-DIFLUOROTETRAHYDROURIDINES | OTSUKA PHARMA CO LTD (JP) | 2018-12-05 | — | — | EP | claimed |
| EP-2727915-B1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | claimed |
| EP-2727915-A1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | Concert Pharmaceuticals Inc. (US) | 2014-05-07 | — | — | EP | claimed |
| EP-2499120-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | Novadex Pharmaceuticals AB (SE) | 2012-09-19 | — | — | EP | claimed |
| US-12637453-B2 | Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12637463-B2 | Tricyclic kinase inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260137789-A1 | BRUSH PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-05-21 | — | — | US | disclosed |
| US-4110533-A | PROCESS FOR THE MANUFACTURE OF ENOL DERIVATIVES | CIBA-GEIGY CORPORATION (US) | 1978-08-29 | — | — | US | disclosed |
| US-4014874-A | Process for the manufacture of 3-substituted thiomethyl-7-amino-2-cephem-4-carboxylic acid compound | CIBA-GEIGY CORPORATION (US) | 1977-03-29 | — | — | US | disclosed |
| US-3989710-A | POSTEMERGENCE HERBICIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-02 | — | — | US | disclosed |
| US-3856848-A | PROCESS FOR PREPARING A PROTECTED ARGININE | LILLY CO ELI | 1974-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137789-A1 | BRUSH PRODRUGS AND USES THEREOF | ABCB11, SLC10A2, CES2 | NPC1 295/4885POLB 701/4885RAB9A 2684/4885 |
| US-12637463-B2 | Tricyclic kinase inhibitors and uses thereof | CDK1, CDK11A, CDK11B | NPC1 1147/4885POLB 292/4885RAB9A 2872/4885 |
| US-20260035402-A1 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | MALT1, CCR10, CYP51A1 | NPC1 12/4885POLB 3335/4885RAB9A 159/4885 |
| US-20220332747-A1 | MACROLIDES AND METHODS OF THEIR PREPARATION AND USE | CYP11B2, ERG28, DHCR7 | NPC1 141/4885POLB 2891/4885RAB9A 3544/4885 |
| US-11634449-B2 | Macrolides and methods of their preparation and use | CYP11B2, ERG28, DHCR7 | NPC1 141/4885POLB 2891/4885RAB9A 3544/4885 |
| US-11241435-B2 | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis | SOST, SIK2, SIK1 | NPC1 2544/4885POLB 4210/4885RAB9A 1608/4885 |
| US-12637453-B2 | Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof | MAP3K1, MAP3K3, MAPK1 | NPC1 1455/4885POLB 1281/4885RAB9A 1073/4885 |
| US-12060334-B2 | 3-substituted phenazine derivatives as antimicrobial agents | ROS1, NOX4, NOX5 | NPC1 2759/4885POLB 597/4885RAB9A 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.